Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. 2000

B D Blackhart, and L Ruslim-Litrus, and C C Lu, and V L Alves, and W Teng, and R M Scarborough, and E E Reynolds, and D Oksenberg
COR Therapeutics, Inc., South San Francisco, California 94080, USA.

The protease-activated thrombin receptor-1 (PAR-1) can be activated by both the tethered ligand exposed by thrombin cleavage and a synthetic peptide having the tethered ligand sequence (thrombin receptor agonist peptide or TRAP). We conducted a mutational analysis of extracellular residues of the receptor potentially involved in interaction with both the tethered ligand and the soluble peptide agonist. Agonist-stimulated calcium efflux in X. laevis oocytes or inositol phosphate accumulation in COS-7 cells was used to assess receptor activation. We have also examined the binding of a radiolabeled TRAP for the wild-type and mutant PAR-1 receptors. Our results indicated that most of the mutations strongly affected TRAP-induced responses without significantly altering thrombin-induced responses or TRAP binding. Several point mutations and deletion of extracellular domains (DeltaEC3, DeltaNH3) drastically altered the ability of mutant receptors to respond to TRAP, but not to thrombin, and did not affect the affinity for the radiolabeled TRAP by these mutant receptors. Only mutations that disrupted the putative disulfide bond or substitution of multiple acidic residues in the second extracellular loop by alanine had a significant effect on both ligand binding and thrombin activation. These results suggest that although both agonists can activate PAR-1, there are profound differences in the ability of thrombin and TRAP to activate PAR-1. In addition, we have found PAR-1 mutants with the ability to dissociate receptor-specific binding from functional activity.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009865 Oocytes Female germ cells derived from OOGONIA and termed OOCYTES when they enter MEIOSIS. The primary oocytes begin meiosis but are arrested at the diplotene state until OVULATION at PUBERTY to give rise to haploid secondary oocytes or ova (OVUM). Ovocytes,Oocyte,Ovocyte
D010716 Phosphatidylinositols Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to the hexahydroxy alcohol, myo-inositol. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid, myo-inositol, and 2 moles of fatty acids. Inositide Phospholipid,Inositol Phosphoglyceride,Inositol Phosphoglycerides,Inositol Phospholipid,Phosphoinositide,Phosphoinositides,PtdIns,Inositide Phospholipids,Inositol Phospholipids,Phosphatidyl Inositol,Phosphatidylinositol,Inositol, Phosphatidyl,Phosphoglyceride, Inositol,Phosphoglycerides, Inositol,Phospholipid, Inositide,Phospholipid, Inositol,Phospholipids, Inositide,Phospholipids, Inositol
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.

Related Publications

B D Blackhart, and L Ruslim-Litrus, and C C Lu, and V L Alves, and W Teng, and R M Scarborough, and E E Reynolds, and D Oksenberg
January 1993, The Biochemical journal,
B D Blackhart, and L Ruslim-Litrus, and C C Lu, and V L Alves, and W Teng, and R M Scarborough, and E E Reynolds, and D Oksenberg
January 2004, American journal of physiology. Cell physiology,
B D Blackhart, and L Ruslim-Litrus, and C C Lu, and V L Alves, and W Teng, and R M Scarborough, and E E Reynolds, and D Oksenberg
February 2002, Journal of neurochemistry,
B D Blackhart, and L Ruslim-Litrus, and C C Lu, and V L Alves, and W Teng, and R M Scarborough, and E E Reynolds, and D Oksenberg
January 2017, International journal of cell biology,
B D Blackhart, and L Ruslim-Litrus, and C C Lu, and V L Alves, and W Teng, and R M Scarborough, and E E Reynolds, and D Oksenberg
January 2008, Biochemical pharmacology,
B D Blackhart, and L Ruslim-Litrus, and C C Lu, and V L Alves, and W Teng, and R M Scarborough, and E E Reynolds, and D Oksenberg
July 2005, The Journal of biological chemistry,
B D Blackhart, and L Ruslim-Litrus, and C C Lu, and V L Alves, and W Teng, and R M Scarborough, and E E Reynolds, and D Oksenberg
December 2000, Molecular pharmacology,
B D Blackhart, and L Ruslim-Litrus, and C C Lu, and V L Alves, and W Teng, and R M Scarborough, and E E Reynolds, and D Oksenberg
January 2006, The Journal of thoracic and cardiovascular surgery,
B D Blackhart, and L Ruslim-Litrus, and C C Lu, and V L Alves, and W Teng, and R M Scarborough, and E E Reynolds, and D Oksenberg
July 1998, The Biochemical journal,
B D Blackhart, and L Ruslim-Litrus, and C C Lu, and V L Alves, and W Teng, and R M Scarborough, and E E Reynolds, and D Oksenberg
March 2003, Current medicinal chemistry. Cardiovascular and hematological agents,
Copied contents to your clipboard!